August 17, 2020Open Access
View Full PaperAngiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction
Structured PICO
Does sacubitril/valsartan reduce the risk of renal events and slow the decline in eGFR in patients with heart failure with preserved ejection fraction compared to valsartan?
P
Population
Patients with heart failure with preserved ejection fraction
I
Intervention
Sacubitril/valsartan
C
Comparator
Valsartan
O
Outcome
Renal events and decline in eGFR
Sacubitril/valsartan provides renal protective benefits by reducing renal events and slowing eGFR decline in patients with HFpEF compared to valsartan alone.
Abstract
In patients with heart failure with preserved ejection fraction, sacubitril/valsartan reduced the risk of renal events, and slowed decline in eGFR, in comparison with valsartan. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920711.